Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.
Yaras S, Demir M, Barutcu S, Yildirim AE, Gurel S, Ucbilek E, Kurtulmus IA, Kayhan MA, Vatansever S, Adanir H, Danis N, Duman S, Turan I, Ari D, Kose S, Alkim H, Harputluoglu MM, Dilber F, Akyildiz M, Cosar AM, Durak S, Sirin G, Kefeli A, Gokcan H, Avcioglu U, Ayyildiz T, Sezgin O, Akarsu M, Dincer D, Guzelbulut F, Gunsar F, Akarca US, Idilman R. Yaras S, et al. Among authors: demir m. Hepatol Forum. 2023 Sep 20;4(3):92-96. doi: 10.14744/hf.2023.2023.0001. eCollection 2023. Hepatol Forum. 2023. PMID: 37822314 Free PMC article.
Characteristics of patients with hepatocellular carcinoma: A multicenter study.
Guzelbulut F, Karaogullarindan U, Akkiz H, Altintas E, Demirtas CO, Bahadir O, Keklikkiran C, Yildirim AE, Gumussoy M, Balci HR, Gokcen P, Gokce DT, Simsek C, Turan I, Can G, Gokbulut V, Yaras S, Adali G, Akdogan RA, Avcioglu U, Demir M, Doganay HL, Vatansever S, Sumer H, Dilber F, Kayhan MA, Balaban HY, Simsek H, Ozdogan OC, Akarca US, Karasu Z, Gunsar F, Idilman R. Guzelbulut F, et al. Among authors: demir m. Hepatol Forum. 2022 Sep 23;3(3):71-76. doi: 10.14744/hf.2022.2022.0028. eCollection 2022 Sep. Hepatol Forum. 2022. PMID: 36177097 Free PMC article.
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
Idilman R, Demir M, Aladag M, Erol C, Cavus B, Iliaz R, Koklu H, Cakaloglu Y, Sahin M, Ersoz G, Koksal İ, Karasu Z, Ozgenel M, Turan İ, Gunduz F, Ataseven H, Akdogan M, Kiyici M, Koksal AS, Akhan S, Gunsar F, Tabak F, Kaymakoglu S, Akarca US; Early Access Program (EAP) Study Groupa. Idilman R, et al. Among authors: demir m. J Viral Hepat. 2019 Jun;26(6):666-674. doi: 10.1111/jvh.13075. Epub 2019 Mar 8. J Viral Hepat. 2019. PMID: 30740820
Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Değertekin B, Demir M, Akarca US, Kani HT, Üçbilek E, Yıldırım E, Güzelbulut F, Balkan A, Vatansever S, Danış N, Demircan M, Soylu A, Yaras S, Kartal A, Kefeli A, Gündüz F, Yalçın K, Erarslan E, Aladağ M, Harputluoğlu M, Özakyol A, Temel T, Akarsu M, Sümer H, Akın M, Albayrak B, Sen İ, Alkım H, Uyanıkoğlu A, Irak K, Öztaşkın S, Uğurlu ÇB, Güneş Ş, Gürel S, Nuriyev K, İnci İ, Kaçar S, Dinçer D, Doğanay L, Göktürk HS, Mert A, Coşar AM, Dursun H, Atalay R, Akbulut S, Balkan Y, Koklu H, Şimşek H, Özdoğan O, Çoban M. Değertekin B, et al. Among authors: demir m. Turk J Gastroenterol. 2020 Dec;31(12):883-893. doi: 10.5152/tjg.2020.20696. Turk J Gastroenterol. 2020. PMID: 33626001 Free PMC article.
NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.
Sayan M, Yıldırım FS, Akhan S, Yıldırım AA, Şirin G, Cabalak M, Demir M, Can S, Ersöz G, Altıntaş E, Ensaroğlu F, Akbulut A, Şener A, Deveci A. Sayan M, et al. Among authors: demir m. Int J Infect Dis. 2020 Jun;95:84-89. doi: 10.1016/j.ijid.2020.03.061. Epub 2020 Apr 14. Int J Infect Dis. 2020. PMID: 32302766 Free article.
Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B.
Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, Guner R, Dogan Z, Kucukazman M, Poyrazoglu OK, Biyik M, Ozturk NA, Aydogan T, Coban S, Kocaman O, Sapmaz F, Gokturk SH, Karaca C, Demirezer A, Tanoglu A, Yildirim B, Altinbas A, Atak BM, Cosar AM, Alkan E; Other collaborators. Koklu S, et al. Among authors: demir m. Aliment Pharmacol Ther. 2015 Feb;41(3):310-9. doi: 10.1111/apt.13036. Epub 2014 Dec 4. Aliment Pharmacol Ther. 2015. PMID: 25982037 Free article.
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Köklü S, et al. Among authors: demir m. Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003. Epub 2012 Oct 9. Clin Gastroenterol Hepatol. 2013. PMID: 23063679
1,389 results